S&P 500   4,655.27
DOW   35,135.94
QQQ   399.69
S&P 500   4,655.27
DOW   35,135.94
QQQ   399.69
S&P 500   4,655.27
DOW   35,135.94
QQQ   399.69
S&P 500   4,655.27
DOW   35,135.94
QQQ   399.69
NASDAQ:IDXX

IDEXX Laboratories Stock Forecast, Price & News

$631.30
+23.78 (+3.91%)
(As of 11/29/2021 04:00 PM ET)
Add
Compare
Today's Range
$609.11
$636.43
50-Day Range
$607.52
$682.58
52-Week Range
$447.82
$706.95
Volume
370,449 shs
Average Volume
395,653 shs
Market Capitalization
$53.53 billion
P/E Ratio
72.31
Dividend Yield
N/A
Beta
0.93
30 days | 90 days | 365 days | Advanced Chart
Receive IDXX News and Ratings via Email

Sign-up to receive the latest news and ratings for IDEXX Laboratories and its competitors with MarketBeat's FREE daily newsletter.


IDEXX Laboratories logo

About IDEXX Laboratories

IDEXX Laboratories, Inc. engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy and water testing markets. It operates through the following segments: CAG, Water, LPD, and Other. The CAG segment develops, designs, manufactures, and distributes products and performs services for veterinarians and the biomedical analytics market, primarily related to diagnostics and information management. The Water segment develops, designs, manufactures, and distributes a range of products used in the detection of various microbiological parameters in water. The LPD segment develops, designs, manufactures, and distributes diagnostic tests and related instrumentation and performs services, which are used to manage the health status of livestock and poultry, to improve producer, and to ensure the quality and safety of milk and food. The Other operating segment combines and presents products for the human point-of-care medical diagnostics market with its out-licensing arrangements. The company was founded by David Evans Shaw on December 19, 1983 and is headquartered in Westbrook, ME.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:IDXX
CUSIP
45168D10
Employees
9,300
Year Founded
1983

Sales & Book Value

Annual Sales
$2.71 billion
Cash Flow
$8.06 per share
Book Value
$8.91 per share

Profitability

Net Income
$581.78 million
Pretax Margin
28.33%

Debt

Price-To-Earnings

Miscellaneous

Free Float
83,047,000
Market Cap
$53.53 billion
Optionable
Optionable

Company Calendar

Last Earnings
11/02/2021
Today
11/30/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/01/2022

Social Links


MarketRank

Overall MarketRank

2.00 out of 5 stars

Medical Sector

368th out of 1,392 stocks

Diagnostic Substances Industry

4th out of 25 stocks

Analyst Opinion: 1.3Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.3 5 -4 -3 -2 -1 -












IDEXX Laboratories (NASDAQ:IDXX) Frequently Asked Questions

Is IDEXX Laboratories a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last twelve months. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" IDEXX Laboratories stock.
View analyst ratings for IDEXX Laboratories
or view top-rated stocks.

How has IDEXX Laboratories' stock been impacted by COVID-19?

IDEXX Laboratories' stock was trading at $245.58 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, IDXX shares have increased by 157.1% and is now trading at $631.30.
View which stocks have been most impacted by COVID-19
.

When is IDEXX Laboratories' next earnings date?

IDEXX Laboratories is scheduled to release its next quarterly earnings announcement on Tuesday, February 1st 2022.
View our earnings forecast for IDEXX Laboratories
.

How were IDEXX Laboratories' earnings last quarter?

IDEXX Laboratories, Inc. (NASDAQ:IDXX) posted its earnings results on Tuesday, November, 2nd. The company reported $2.03 EPS for the quarter, topping the Zacks' consensus estimate of $1.88 by $0.15. The firm earned $810.42 million during the quarter, compared to the consensus estimate of $793.26 million. IDEXX Laboratories had a net margin of 24.14% and a trailing twelve-month return on equity of 106.60%. During the same period last year, the business posted $1.69 EPS.
View IDEXX Laboratories' earnings history
.

How will IDEXX Laboratories' stock buyback program work?

IDEXX Laboratories announced that its Board of Directors has initiated a share buyback plan on Wednesday, February 12th 2020, which authorizes the company to repurchase 5,000,000 shares, according to EventVestor. This repurchase authorization authorizes the company to buy shares of its stock through open market purchases. Shares repurchase plans are typically a sign that the company's board believes its shares are undervalued.

What guidance has IDEXX Laboratories issued on next quarter's earnings?

IDEXX Laboratories issued an update on its FY 2021 earnings guidance on Tuesday, November, 9th. The company provided EPS guidance of $8.300-$8.380 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $8.380. The company issued revenue guidance of $3.19 billion-$3.20 billion, compared to the consensus revenue estimate of $3.20 billion.

What price target have analysts set for IDXX?

6 analysts have issued 1-year price objectives for IDEXX Laboratories' stock. Their forecasts range from $570.00 to $770.00. On average, they expect IDEXX Laboratories' share price to reach $686.40 in the next twelve months. This suggests a possible upside of 8.7% from the stock's current price.
View analysts' price targets for IDEXX Laboratories
or view top-rated stocks among Wall Street analysts.

Who are IDEXX Laboratories' key executives?

IDEXX Laboratories' management team includes the following people:
  • Jonathan J. Mazelsky, President, Chief Executive Officer & Director
  • John Hart, Senior Vice President-Worldwide Operations
  • Brian Patrick McKeon, Chief Financial Officer, Treasurer & Executive VP
  • Jeffrey Thomas, Chief Technology Officer & Senior VP
  • Ken Grady, Chief Information Officer & Senior VP

What is Jay Mazelsky's approval rating as IDEXX Laboratories' CEO?

40 employees have rated IDEXX Laboratories CEO Jay Mazelsky on Glassdoor.com. Jay Mazelsky has an approval rating of 69% among IDEXX Laboratories' employees.

What other stocks do shareholders of IDEXX Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IDEXX Laboratories investors own include NVIDIA (NVDA), Netflix (NFLX), PayPal (PYPL), Mastercard (MA), Adobe (ADBE), Tesla (TSLA), Alibaba Group (BABA), Square (SQ), Walt Disney (DIS) and Shopify (SHOP).

What is IDEXX Laboratories' stock symbol?

IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX."

Who are IDEXX Laboratories' major shareholders?

IDEXX Laboratories' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (10.25%), Fundsmith LLP (5.00%), Bamco Inc. NY (3.06%), Geode Capital Management LLC (2.09%), Alliancebernstein L.P. (1.58%) and Franklin Resources Inc. (1.53%). Company insiders that own IDEXX Laboratories stock include Brian P Mckeon, Brian P Mckeon, Bruce L Claflin, Daniel M Junius, Giovani Twigge, James F Polewaczyk, Jonathan Jay Mazelsky, Jonathan W Ayers, Kathy V Turner, Kathy V Turner, M Anne Szostak, Michael Lane, Nimrata Hunt, Rebecca M Henderson and Sophie V Vandebroek.
View institutional ownership trends for IDEXX Laboratories
.

Which institutional investors are selling IDEXX Laboratories stock?

IDXX stock was sold by a variety of institutional investors in the last quarter, including Congress Asset Management Co. MA, Natixis, Bamco Inc. NY, Neuberger Berman Group LLC, Putnam Investments LLC, Eagle Asset Management Inc., Principal Financial Group Inc., and Royal Bank of Canada. Company insiders that have sold IDEXX Laboratories company stock in the last year include Brian P Mckeon, Daniel M Junius, Giovani Twigge, James F Polewaczyk, Jonathan Jay Mazelsky, Jonathan W Ayers, Kathy V Turner, M Anne Szostak, Michael Lane, Nimrata Hunt, Rebecca M Henderson, and Sophie V Vandebroek.
View insider buying and selling activity for IDEXX Laboratories
or view top insider-selling stocks.

Which institutional investors are buying IDEXX Laboratories stock?

IDXX stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Arrowstreet Capital Limited Partnership, Alliancebernstein L.P., Bank of New York Mellon Corp, AXA S.A., Geode Capital Management LLC, Caisse DE Depot ET Placement DU Quebec, and Jane Street Group LLC.
View insider buying and selling activity for IDEXX Laboratories
or or view top insider-buying stocks.

How do I buy shares of IDEXX Laboratories?

Shares of IDXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is IDEXX Laboratories' stock price today?

One share of IDXX stock can currently be purchased for approximately $631.30.

How much money does IDEXX Laboratories make?

IDEXX Laboratories has a market capitalization of $53.53 billion and generates $2.71 billion in revenue each year. The company earns $581.78 million in net income (profit) each year or $8.73 on an earnings per share basis.

How many employees does IDEXX Laboratories have?

IDEXX Laboratories employs 9,300 workers across the globe.

When was IDEXX Laboratories founded?

IDEXX Laboratories was founded in 1983.

What is IDEXX Laboratories' official website?

The official website for IDEXX Laboratories is www.idexx.com.

Where are IDEXX Laboratories' headquarters?

IDEXX Laboratories is headquartered at ONE IDEXX DRIVE, WESTBROOK ME, 04092.

How can I contact IDEXX Laboratories?

IDEXX Laboratories' mailing address is ONE IDEXX DRIVE, WESTBROOK ME, 04092. The company can be reached via phone at (207) 556-0300, via email at [email protected], or via fax at 207-556-4346.


This page was last updated on 11/30/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.